Dementia Research in Scotland
The AFFECT trial aims to test whether a commonly used treatment for high blood pressure and chest pain can double up as a treatment for people with vascular dementia.
The Boehringer Ingelheim 1289.7 Drug Trial is a research study testing the effect of a new drug, BI 409306, in people with Alzheimer’s disease by comparison to a placebo, an inactive substance. The purpose is to find out if this new investigational drug is safe and effective in people with mild Alzheimer’s disease at different dose levels and can become an additional treatment to enhance existing drugs.
The MADE (Minocycline in Alzheimer’s Disease Efficacy) trial is a multi-centre, randomised, controlled trial in very mild Alzheimer’s Disease. It aims to determine whether the antibiotic drug Minocycline is effective in reducing the rate of cognitive and functional decline over a 2-year period and assess the safety and tolerability of Minocycline.
The IDEAL study investigates what helps people to live well with dementia. It is the first large-scale project of its kind, and what the researchers find out will be used to guide policy and practice for helping people deal with dementia. NHS staff visit volunteers in their home to talk about dementia, and what can really help make life easier and more fulfilling. Researchers will visit three times, twelve months apart, and talk to both volunteers and family members or friends, and bring questionnaires for completion. Each new visit, they will be interested to learn about what has changed. You can find out more by visiting the IDEAL project online.
The AMARANTH drug trial is testing whether an experimental drug (AZD3293 [LY3314814]) is safe and effective in slowing down the progression of Alzheimer’s disease. The investigational drug is designed to reduce the creation of substances that will eventually become amyloid, a brain protein known to build up in excessive amounts in those with, or at risk of, Alzheimer’s disease. The drug may therefore slow down the deterioration of the brain in people with early Alzheimer’s disease. The trial is for people aged between 55-85 with mild Alzheimer’s Disease or Mild Cognitive Impairment, and is being conducted worldwide.
The purpose of the DeNDRoN 3129 Lundbeck Starbeam study is to find out whether a new research drug given in addition to the current medication Donepezil, can improve the cognitive function in people with Alzheimer’s disease. The drug, Idaloperidin, has already been shown to improve cognitive performance when administered in conjunction with Donepezil in a randomised controlled trial with patients who had moderate Alzheimer’s Disease.
The DeNDRoN 2347 Merck MK-8931-019 study aims to test a new medication (MK8931) in the treatment of Mild Cognitive Impairment. This medication acts to reduce the levels of a brain protein called amyloid, which is known to build up in excessive amounts in those with, or at risk of, Alzheimer’s disease. Volunteers are sought who are between 50 and 85, with mild memory problems or Mild Cognitive Impairment.
The RADAR study is a new ground-breaking clinical trial, which is examining how a commonly used blood pressure drug called losartan could slow down the rate of progression in Alzheimer’s disease. The study is testing whether the drug reduces rates of brain shrinkage, vascular damage (affecting the blood vessels) and cognitive impairment that are all common features in Alzheimer’s disease. The study is looking for participants who are aged 55 and above with a diagnosis of Alzheimer’s disease. Participants do not have to have high blood pressure or if they are taking certain drugs for their blood pressure, they may still be able to take part.
You can see if you are eligible for any of these studies – and others around the nation by logging into your Join Dementia Research account. If you haven’t yet registered with Join Dementia Research, why not sign up today?
You can sign up online or by calling Alzheimer Scotland helpline on 0808 808 3 000.